Misunderstanding the Bipartisan Senate Report on Drug Prices. See Also: Incyte Signs a Promising Collaborative Agreement with Merus N.V.

Observing the biotech sector’s stock prices post losses yesterday, Wednesday, Dec. 21 convinced us that investors and traders in the biotech sector might have wrongly interpreted a bipartisan Senate report regarding the high price of drugs.

The report is the outcome of a study that forms the basis of a recommendation that would enable the Congress take the right action against unjustified increases in the prices of decades-old prescription medicines that are still used for certain diseases and have no competition.

Decade old drugs is what investors missed to hear. They surely . . .

This content is for paid subscribers.
Please click here to subscribe or here to log in.